Related Experiment Video
Updated: Aug 27, 2025
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
MicroRNAs as a New Target for Alzheimer's Disease Treatment
Behrouz Shademan1, Cigir Biray Avci1, Vahidreza Karamad1
1Department of Medical Biology, Faculty of Medicine, EGE University, Izmir, Turkey.
Abstract:
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease associated with advanced age. It is characterized by cognitive decline and memory loss and accounts for most cases of dementia in older people. AD can be rooted in genetic, epigenetic, or environmental causes. No drugs or other therapeutic agents prevent or delay AD progression. MicroRNAs (miRNAs) are short and uncoded RNAs that can bind to 200 RNAs approximately. By inhibiting or destroying specific messenger RNAs (mRNAs), they control gene expression and broadly affect cellular functions. MiRNAs play important roles in regulating neuronal growth, neuronal differentiation, dendritic spine morphology, and synaptic flexibility in the nervous system. The expression levels of miRNAs are changed in neurological diseases, including AD, suggesting that they play an essential role in the pathogenesis of the disease. Therefore, targeting disrupted miRNAs may be a novel therapeutic approach against AD and offers multiple solutions, including harnessing the beneficial effects of beta-amyloid, reducing tau protein, reducing neuronal cell death, and protecting synapses in AD.
Insights
Alzheimer's disease (AD) involves neurodegeneration and memory loss. Targeting microRNAs (miRNAs) offers a novel therapeutic strategy to combat AD by regulating gene expression and protecting brain cells.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a prevalent, age-related neurodegenerative disorder causing cognitive decline and dementia.
- Current treatments cannot prevent or reverse AD progression, highlighting the need for novel therapeutic strategies.
- MicroRNAs (miRNAs) are key regulators of gene expression with critical roles in nervous system function.
Purpose of the Study:
- To explore the role of microRNAs (miRNAs) in Alzheimer's disease (AD) pathogenesis.
- To investigate the potential of targeting dysregulated miRNAs as a therapeutic approach for AD.
Main Methods:
- Review of current literature on miRNA function and their involvement in neurological diseases.
- Analysis of the regulatory mechanisms of miRNAs in neuronal processes relevant to AD.
- Exploration of potential therapeutic benefits of miRNA modulation in AD models.
Main Results:
- Altered miRNA expression levels are observed in Alzheimer's disease (AD), implicating them in disease progression.
- MiRNAs influence crucial cellular functions including neuronal growth, differentiation, and synaptic plasticity.
- Modulating specific miRNAs could offer multifaceted therapeutic benefits for AD.
Conclusions:
- Dysregulated miRNAs are integral to Alzheimer's disease (AD) pathology.
- Targeting aberrant miRNAs presents a promising novel therapeutic avenue for AD.
- MiRNA-based therapies may address key pathological features of AD, including amyloid-beta, tau, and synaptic dysfunction.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22MicroRNAs